SavedAdd your journal

Journals / ACH Medical journal / 2026 / Volume: 3 Issue: 2

The effect of maternal asthma on serum PAPP-A levels and first trimester aneuploidy screening test running

Bergen Laleli Koç(Ankara Bilkent Şehir Hastanesi)0000-0001-8029-7489
Gonca Türker Ergün(Ankara Bilkent Şehir Hastanesi)0000-0003-1064-8727
Özgür Kara(Ankara Bilkent Şehir Hastanesi)0000-0002-4204-0014
Atakan Tanaçan(Ankara Bilkent Şehir Hastanesi)0000-0001-8209-8248
Deniz Oluklu(Ankara Bilkent Şehir Hastanesi)0000-0002-9050-2041
Betül Akgün Aktaş(Ankara Bilkent Şehir Hastanesi)0000-0003-4523-011X
Ecem Kaya(Ankara Bilkent Şehir Hastanesi)0000-0001-9622-599X
Dilek Sahin(Ankara Bilkent Şehir Hastanesi)0000-0001-8567-9048
Pages
—
Publication Date
2024-06-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on the results of our study, the first-trimester fetal aneuploidy screening test is a reliable screening method for pregnant women with asthma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: PAPP-A (Pregnancy-associated plasma protein-A) is considered a pro-inflammatory marker and its serum levels are elevated in non-pregnant patients with asthma.
📊
Key Findings & Data:In the second step, the groups compared whether PAPP-A and fβ-HCG ( free β human chorionic gonadotropin) levels were below or above the cut-off values for Trisomy 21 and compared them according to maternal age (<35; ≥35).
💡
Conclusion & Impact:Based on the results of our study, the first-trimester fetal aneuploidy screening test is a reliable screening method for pregnant women with asthma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Aneuploidy screening · Asthma · PAPP-A

Abstract

INTRODUCTION: PAPP-A (Pregnancy-associated plasma protein-A) is considered a pro-inflammatory marker and its serum levels are elevated in non-pregnant patients with asthma. In the current research, we aimed to investigate whether maternal serum PAPP-A levels, a biomarker for first-trimester aneuploidy screening, differ in pregnant women with asthma compared to healthy pregnant women. METHODS: In the first step, maternal serum PAPP-A MoM values, used as the first-trimester fetal aneuploidy screening marker, were compared between pregnant women with asthma and a healthy pregnant group. In the second step, the groups compared whether PAPP-A and fβ-HCG ( free β human chorionic gonadotropin) levels were below or above the cut-off values for Trisomy 21 and compared them according to maternal age (<35; ≥35). RESULTS: The median PAPP-A level was found to be 2.15 IU/L (0.41-9.91) in the asthma group and 2.54 IU/L (0.56-11.40) in the control group, and there was no difference between the groups (P=0.363). The median PAPP-A MoM value was 0.99 (0.15-3.28) in the asthma group and 1.07 (0.33-3.37) in the control group. This result did not show a statistically significant difference (P = 0.694). No statistically significant difference was shown between the groups below and above 35 age (P=0.456). DISCUSSION AND CONCLUSION: Maternal serum PAPP-A levels in pregnant women with asthma do not vary compared to the healthy pregnant group without asthma. Based on the results of our study, the first-trimester fetal aneuploidy screening test is a reliable screening method for pregnant women with asthma.

🔖

Cite This Article

Koç, B. L., Ergün, G. T., Kara, Ö., Tanaçan, A., Oluklu, D., Aktaş, B. A., Kaya, E., Sahin, D. (2024). The effect of maternal asthma on serum PAPP-A levels and first trimester aneuploidy screening test running. ACH Medical journal, Volume: 3 Issue: 2. https://ajindex.com/articles/1628839

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Schatz M, Dombrowski MP, Wise R, et al.: Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol. 2003, 112:283-288. 10.1067/mai.2003.1516
  2. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol. 2005, 115:34-46. 10.1016/j.jaci.2004.10.023
  3. Canick JA, Lambert-Messerlian GM, Palomaki GE, et al.: Comparison of serum markers in first-trimester down syndrome screening. Obstet Gynecol. 2006, 108:1192-1199. 10.1097/01.AOG.0000241095.19638.f2
  4. Wapner R, Thom E, Simpson JL, et al.: First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003, 349:1405-1413. 10.1056/NEJMoa025273
  5. Kirkegaard I, Uldbjerg N, Oxvig C: Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview. Acta Obstet Gynecol Scand. 2010, 89:1118-1125. 10.3109/00016349.2010.505639
  6. Coskun A, Balbay O, Duran S, et al.: Pregnancy-associated plasma protein-A and asthma. Adv Ther. 2007, 24:362-367. 10.1007/bf02849905
  7. Lin TM, Galbert SP, Kiefer D, Spellacy WN, Gall S: Characterization of four human pregnancy-associated plasma proteins. Am J Obstet Gynecol. 1974, 118:223-236. 10.1016/0002-9378(74)90553-5
  8. Krantz DA, Larsen JW, Buchanan PD, Macri JN: First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol. 1996, 174:612-616. 10.1016/s0002-9378(96)70436-2
  9. Spencer K, Ong C, Skentou H, Liao AW, K HN: Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 2000, 20:411-416.
  10. Tul N, Spencer K, Noble P, Chan C, Nicolaides K: Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 1999, 19:1035-1042. 10.1002/(sici)1097-0223(199911)19:11 3.0.co;2-2
  11. Dugoff L, Hobbins JC, Malone FD, et al.: First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004, 191:1446-1451. 10.1016/j.ajog.2004.06.052
  12. ATAMAN YILDIRIM Z, TUĞRUL ERSAK D, TİMUR B, KAHYAOĞLU S: The Predictive Value of First and Second Trimester Screening Test Biomarkers in Preeclampsia. Forbes Journal of Medicine. 2022, 3.
  13. D'Antonio F, Rijo C, Thilaganathan B, et al.: Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications. Prenat Diagn. 2013, 33:839-847. 10.1002/pd.4141
  14. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C: Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001, 276:21849-21853. 10.1074/jbc.M102191200
  15. Hjortebjerg R: IGFBP-4 and PAPP-A in normal physiology and disease. Growth Horm IGF Res. 2018, 41:7-22. 10.1016/j.ghir.2018.05.002
  16. Bischof P, DuBerg S, Herrmann W, Sizonenko PC: Pregnancy-associated plasma protein-A (PAPP-A) and hCG in early pregnancy. Br J Obstet Gynaecol. 1981, 88:973-975. 10.1111/j.1471-0528.1981.tb01683.x
  17. Overgaard MT, Oxvig C, Christiansen M, et al.: Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. Biol Reprod. 1999, 61:1083-1089. 10.1095/biolreprod61.4.1083
  18. Conover CA, Harrington SC, Bale LK: Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells. Growth Horm IGF Res. 2008, 18:213-220. 10.1016/j.ghir.2007.09.001
  19. Talay F, Tosun M, Yaşar ZA, et al.: Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity. Inflammation. 2016, 39:1130-1133. 10.1007/s10753-016-0345-z
  20. Bulut I, Ozseker ZF, Coskun A, Serteser M, Unsal I: Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab. J Asthma. 2018, 55:1116-1121. 10.1080/02770903.2017.1396471
  21. Li Y, Zhou C, Zhou X, Song L, Hui R: PAPP-A in cardiac and non-cardiac conditions. Clin Chim Acta. 2013, 417:67-72. 10.1016/j.cca.2012.12.006
  22. Gutiérrez-Leonard H, Martínez-Lara E, Fierro-Macías AE, et al.: Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease. Ir J Med Sci. 2017, 186:597-605. 10.1007/s11845-016-1515-6
  23. Hjortebjerg R, Rasmussen LM, Gude MF, et al.: Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients. J Clin Endocrinol Metab. 2020, 105. 10.1210/clinem/dgaa617